UBXN2B

Summary

UBXN2B (UBX domain protein 2B, HGNC:27035) is a protein-coding gene on chromosome 8q12.1, encoding UBX domain-containing protein 2B (Q14CS0). Adapter protein required for Golgi and endoplasmic reticulum biogenesis.

Predicted to enable ubiquitin binding activity. Involved in establishment of mitotic spindle orientation; negative regulation of protein localization to centrosome; and positive regulation of mitotic centrosome separation. Predicted to be located in Golgi apparatus; endoplasmic reticulum; and spindle pole centrosome. Predicted to be active in cytosol and nucleus.

Source: NCBI Gene 137886 — RefSeq curated summary.

At a glance

• GWAS associations: 25
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_001077619

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27035
Approved symbol	UBXN2B
Name	UBX domain protein 2B
Location	8q12.1
Locus type	gene with protein product
Status	Approved
Aliases	p37
Ensembl gene	ENSG00000215114
Ensembl biotype	protein_coding
OMIM	610686
Entrez	137886

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000399598, ENST00000520732, ENST00000521796, ENST00000522978, ENST00000523409, ENST00000879980, ENST00000879981, ENST00000920600, ENST00000920601, ENST00000920602, ENST00000920603, ENST00000970427, ENST00000970428

RefSeq mRNA: 3 — MANE Select: NM_001077619 NM_001077619, NM_001330535, NM_001363181

CCDS: CCDS43741, CCDS83297

Canonical transcript exons

ENST00000399598 — 8 exons

Exon	Start	End
ENSE00001539267	58447389	58451501
ENSE00001539291	58411361	58411469
ENSE00003470655	58416850	58416953
ENSE00003558345	58445907	58446068
ENSE00003594189	58434395	58434504
ENSE00003599251	58439633	58439770
ENSE00003625167	58430519	58430669
ENSE00003671774	58433160	58433243

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 95.58.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.9297 / max 517.3836, expressed in 1754 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88987	15.9297	1754

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	95.58	gold quality
blood	UBERON:0000178	93.82	gold quality
ganglionic eminence	UBERON:0004023	92.99	gold quality
monocyte	CL:0000576	92.73	gold quality
mononuclear cell	CL:0000842	92.66	gold quality
leukocyte	CL:0000738	92.45	gold quality
embryo	UBERON:0000922	91.92	gold quality
germinal epithelium of ovary	UBERON:0001304	91.31	gold quality
ventricular zone	UBERON:0003053	90.30	gold quality
Brodmann (1909) area 23	UBERON:0013554	89.98	gold quality
heart right ventricle	UBERON:0002080	88.97	gold quality
pigmented layer of retina	UBERON:0001782	88.96	gold quality
seminal vesicle	UBERON:0000998	88.92	gold quality
bone marrow	UBERON:0002371	88.59	gold quality
bone marrow cell	CL:0002092	88.53	gold quality
entorhinal cortex	UBERON:0002728	88.51	gold quality
orbitofrontal cortex	UBERON:0004167	88.46	gold quality
middle temporal gyrus	UBERON:0002771	88.42	gold quality
parotid gland	UBERON:0001831	88.40	gold quality
primary visual cortex	UBERON:0002436	88.28	gold quality
trabecular bone tissue	UBERON:0002483	88.22	gold quality
tibia	UBERON:0000979	88.05	gold quality
adrenal tissue	UBERON:0018303	88.01	gold quality
biceps brachii	UBERON:0001507	87.83	gold quality
adult organism	UBERON:0007023	87.57	gold quality
occipital lobe	UBERON:0002021	87.41	gold quality
postcentral gyrus	UBERON:0002581	87.40	gold quality
blood vessel layer	UBERON:0004797	87.33	gold quality
superior frontal gyrus	UBERON:0002661	87.28	gold quality
corpus callosum	UBERON:0002336	87.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

206 targeting UBXN2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548J-3P	99.94	72.61	4881

Literature-anchored findings (GeneRIF, showing 3)

• these results demonstrate that p37 phosphorylation on Serine-56 and Threonine-59 is important for Golgi disassembly at mitosis. (PMID:20875789)
• human p37/p47 and their C. elegans orthologue UBXN-2 regulate centrosome function in prophase by limiting the recruitment of Aurora A (PMID:23649807)
• In silico prediction, characterization, docking studies and molecular dynamics simulation of human p97 in complex with p37 cofactor. (PMID:36088301)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ubxn2b	ENSMUSG00000028243
rattus_norvegicus	Ubxn2b	ENSRNOG00000064562
drosophila_melanogaster	p47	FBGN0033179
drosophila_melanogaster	CG42383	FBGN0259729
caenorhabditis_elegans		WBGENE00022381

Paralogs (3): NSFL1C (ENSG00000088833), UBXN11 (ENSG00000158062), UBXN2A (ENSG00000173960)

Protein

Protein identifiers

UBX domain-containing protein 2B — Q14CS0 (reviewed: Q14CS0)

Alternative names: NSFL1 cofactor p37, p97 cofactor p37

All UniProt accessions (4): E5RGJ4, E5RJ36, Q14CS0, H0YAX6

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BET1L. VCPIP1 is also required, but not its deubiquitinating activity. Together with NSFL1C/p47, regulates the centrosomal levels of kinase AURKA/Aurora A during mitotic progression by promoting AURKA removal from centrosomes in prophase. Also, regulates spindle orientation during mitosis.

Subunit / interactions. Interacts with VCP. Does not bind ubiquitin.

Subcellular location. Nucleus. Cytoplasm. Cytosol. Endoplasmic reticulum. Golgi apparatus. Cytoskeleton. Microtubule organizing center. Centrosome.

Similarity. Belongs to the NSFL1C family.

RefSeq proteins (3): NP_001071087, NP_001317464, NP_001350110 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001012	UBX_dom	Domain
IPR012989	SEP_domain	Domain
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR036241	NSFL1C_SEP_dom_sf	Homologous_superfamily

Pfam: PF00789, PF08059

UniProt features (13 total): modified residue 7, domain 2, region of interest 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8B5R	ELECTRON MICROSCOPY	6.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14CS0-F1	70.84	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 231, 234, 235, 2, 56, 59, 66

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 186 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE45365_NK_CELL_VS_CD11B_DC_UP, GOBP_ESTABLISHMENT_OF_SPINDLE_ORIENTATION, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, GOBP_NUCLEAR_MEMBRANE_REASSEMBLY, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_VACUOLE_ORGANIZATION, GOBP_MEMBRANE_BIOGENESIS, GOBP_SPINDLE_LOCALIZATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GOBP_MEMBRANE_FUSION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION

GO Biological Process (8): autophagosome assembly (GO:0000045), establishment of mitotic spindle orientation (GO:0000132), Golgi organization (GO:0007030), nuclear membrane reassembly (GO:0031468), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of mitotic centrosome separation (GO:0046604), membrane fusion (GO:0061025), negative regulation of protein localization to centrosome (GO:1904780)

GO Molecular Function (2): ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (8): nucleus (GO:0005634), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), cytosol (GO:0005829), spindle pole centrosome (GO:0031616), cytoplasm (GO:0005737), centrosome (GO:0005813), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	3
cytoplasm	3
endomembrane system	2
cellular anatomical structure	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
mitotic cell cycle	1
establishment of mitotic spindle localization	1
establishment of spindle orientation	1
organelle organization	1
endomembrane system organization	1
membrane assembly	1
nuclear membrane organization	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
mitotic centrosome separation	1
regulation of mitotic centrosome separation	1
positive regulation of cell cycle process	1
membrane organization	1
protein localization to centrosome	1
negative regulation of protein localization	1
regulation of protein localization to centrosome	1
ubiquitin-like protein binding	1
binding	1
spindle pole	1
centrosome	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

819 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBXN2B	FAM110B	Q8TC76	674
UBXN2B	CDC42BPB	Q9Y5S2	641
UBXN2B	UBXN10	Q96LJ8	625
UBXN2B	UBXN7	O94888	605
UBXN2B	UBXN1	Q04323	598
UBXN2B	UBXN6	Q9BZV1	576
UBXN2B	NSMAF	Q92636	565
UBXN2B	UBXN11	Q5T124	541
UBXN2B	UBXN8	O00124	535
UBXN2B	NCKAP5L	Q9HCH0	532
UBXN2B	ASPSCR1	Q9BZE9	526
UBXN2B	FAF2	Q96CS3	514
UBXN2B	FAF1	Q9UNN5	510
UBXN2B	UBXN4	Q92575	478
UBXN2B	NCKIPSD	Q9NZQ3	462
UBXN2B	SYT5	O00445	462

IntAct

74 interactions, top by confidence:

A	B	Type	Score
VCP	UBXN2B	psi-mi:“MI:0915”(physical association)	0.910
UBXN2B	VCP	psi-mi:“MI:0915”(physical association)	0.910
UBXN2B	VCP	psi-mi:“MI:2364”(proximity)	0.910
VCP	UBXN2B	psi-mi:“MI:2364”(proximity)	0.910
UBXN2B	VCP	psi-mi:“MI:0914”(association)	0.910
NGLY1	UBXN2B	psi-mi:“MI:0915”(physical association)	0.780
UBXN2B	NGLY1	psi-mi:“MI:0915”(physical association)	0.780
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
UBXN2B	INCA1	psi-mi:“MI:0915”(physical association)	0.720
INCA1	UBXN2B	psi-mi:“MI:0915”(physical association)	0.720
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
UBXN2B	VCF1	psi-mi:“MI:0915”(physical association)	0.670
UBXN2B	CRX	psi-mi:“MI:0915”(physical association)	0.560
MEOX1	UBXN2B	psi-mi:“MI:0915”(physical association)	0.560
UBXN2B	VAT1L	psi-mi:“MI:0915”(physical association)	0.560
UBXN2B	MEOX1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (92): UBXN2B (Two-hybrid), UBXN2B (Two-hybrid), UBXN2B (Two-hybrid), UBXN2B (Two-hybrid), UBXN2B (Two-hybrid), INCA1 (Two-hybrid), VCP (Affinity Capture-MS), CDC42BPB (Affinity Capture-MS), NIF3L1 (Affinity Capture-MS), PPP1R7 (Affinity Capture-MS), PPP1R11 (Affinity Capture-MS), ASPSCR1 (Affinity Capture-MS), ACTR6 (Affinity Capture-MS), FAM104A (Affinity Capture-MS), UBXN2B (Affinity Capture-MS)

ESM2 similar proteins: A3KMI0, A8WZU5, A8XY47, A8XYX3, B3M268, D3ZID8, O14045, O15226, O42467, O49413, O59709, O93436, O94536, P0C627, P32524, P32783, P34223, P34511, P68543, P87143, P90740, Q09655, Q0KL01, Q0P3R5, Q14CS0, Q19546, Q23088, Q23541, Q3SWY8, Q5ZLK2, Q61T02, Q6CKI0, Q6P158, Q7Z478, Q8BY02, Q8STL3, Q8WT44, Q8WTJ4, Q96AP4, Q99KJ0

Diamond homologs: D3ZID8, O35987, P0C627, P34223, P68543, Q0KL01, Q0P3R5, Q14CS0, Q3SZC4, Q5RBG3, Q5ZK10, Q5ZLK2, Q7Y175, Q8RWU7, Q99KJ0, Q9CZ44, Q9SUG6, Q9UNZ2, Q9UT81, P0C8Q0, Q54BQ5, Q9N2W5, F4IXN6

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
UBXN2B	“down-regulates activity”	AURKA	binding
CDK1	“down-regulates activity”	UBXN2B	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	5	10.0×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1709 predictions. Top by Δscore:

Variant	Effect	Δscore
8:58411427:G:GT	donor_gain	1.0000
8:58411471:T:A	donor_loss	1.0000
8:58413297:A:AG	acceptor_gain	1.0000
8:58413298:G:GG	acceptor_gain	1.0000
8:58413372:G:GG	donor_gain	1.0000
8:58416848:A:AG	acceptor_gain	1.0000
8:58416848:AGTT:A	acceptor_gain	1.0000
8:58416848:AGTTG:A	acceptor_gain	1.0000
8:58416849:G:GT	acceptor_gain	1.0000
8:58416849:GTT:G	acceptor_gain	1.0000
8:58416849:GTTG:G	acceptor_gain	1.0000
8:58416849:GTTGG:G	acceptor_gain	1.0000
8:58416949:CAACG:C	donor_gain	1.0000
8:58416951:ACG:A	donor_gain	1.0000
8:58416951:ACGG:A	donor_loss	1.0000
8:58416952:CG:C	donor_gain	1.0000
8:58416952:CGGT:C	donor_loss	1.0000
8:58416953:GG:G	donor_gain	1.0000
8:58416953:GGT:G	donor_loss	1.0000
8:58416954:G:GG	donor_gain	1.0000
8:58416954:GT:G	donor_loss	1.0000
8:58416955:TAAGT:T	donor_loss	1.0000
8:58433241:GAT:G	donor_gain	1.0000
8:58434384:A:AG	acceptor_gain	1.0000
8:58434385:T:G	acceptor_gain	1.0000
8:58434501:GAGG:G	donor_gain	1.0000
8:58434503:GG:G	donor_gain	1.0000
8:58434504:GG:G	donor_gain	1.0000
8:58434506:TAAGA:T	donor_loss	1.0000
8:58443314:G:T	donor_gain	1.0000

AlphaMissense

2157 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:58434416:T:A	W149R	0.999
8:58434416:T:C	W149R	0.999
8:58434426:G:A	G152D	0.999
8:58434428:T:C	F153L	0.999
8:58434429:T:C	F153S	0.999
8:58434430:C:A	F153L	0.999
8:58434430:C:G	F153L	0.999
8:58434495:T:A	V175D	0.999
8:58439742:T:C	F215L	0.999
8:58439744:T:A	F215L	0.999
8:58439744:T:G	F215L	0.999
8:58434408:T:C	L146P	0.998
8:58434431:A:C	S154R	0.998
8:58434433:T:A	S154R	0.998
8:58434433:T:G	S154R	0.998
8:58434483:T:C	F171S	0.998
8:58439641:C:G	P181R	0.998
8:58446053:T:C	F273S	0.998
8:58447400:T:A	V282D	0.998
8:58434408:T:A	L146H	0.997
8:58434418:G:C	W149C	0.997
8:58434418:G:T	W149C	0.997
8:58434425:G:C	G152R	0.997
8:58434426:G:T	G152V	0.997
8:58439641:C:A	P181H	0.997
8:58434482:T:C	F171L	0.996
8:58434484:T:A	F171L	0.996
8:58434484:T:G	F171L	0.996
8:58439640:C:A	P181T	0.996
8:58439683:T:C	L195S	0.996

dbSNP variants (sampled 300 via entrez): RS1000078717 (8:58432736 C>A,T), RS1000108107 (8:58438808 G>A,C), RS1000176613 (8:58416248 T>C), RS1000276657 (8:58419844 C>T), RS1000754239 (8:58423727 G>A), RS1000783343 (8:58414799 T>C), RS1000819579 (8:58413286 A>G), RS1000941753 (8:58417353 T>C), RS1001038791 (8:58444874 T>C), RS1001055990 (8:58434338 T>C), RS1001064104 (8:58434960 G>A), RS1001130702 (8:58415002 T>C), RS1001167808 (8:58447724 T>C), RS1001281562 (8:58412853 A>C,G,T), RS1001332748 (8:58440532 A>T)

Disease associations

OMIM: gene MIM:610686 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

25 associations (top):

Study	Trait	p-value
GCST001909_2	Narcolepsy with cataplexy	1.000000e-07
GCST003725_5	Gallstone disease	3.000000e-06
GCST003771_14	Loneliness	5.000000e-06
GCST003807_6	Systolic blood pressure response to hydrochlorothiazide in hypertension	7.000000e-06
GCST006004_14	Low density lipoprotein cholesterol levels	9.000000e-09
GCST006034_36	Total cholesterol levels	5.000000e-18
GCST007931_72	Medication use (HMG CoA reductase inhibitors)	2.000000e-08
GCST008074_61	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	5.000000e-06
GCST008074_76	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	3.000000e-08
GCST008076_42	Triglyceride levels	1.000000e-07
GCST008077_18	LDL cholesterol levels	7.000000e-09
GCST008077_64	LDL cholesterol levels	1.000000e-09
GCST008078_3	LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	2.000000e-23
GCST008078_61	LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	3.000000e-27
GCST008079_10	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	3.000000e-25
GCST008079_48	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2.000000e-30
GCST008079_92	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1.000000e-06
GCST008083_134	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1.000000e-07
GCST008083_53	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2.000000e-06
GCST008086_25	LDL cholesterol levels in current drinkers	1.000000e-13
GCST008086_40	LDL cholesterol levels in current drinkers	4.000000e-13
GCST008087_111	Triglyceride levels in current drinkers	8.000000e-06
GCST008087_24	Triglyceride levels in current drinkers	2.000000e-08
GCST011346_55	Total cholesterol levels	2.000000e-18
GCST011347_32	Low density lipoprotein cholesterol levels	4.000000e-16

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007865	loneliness measurement
EFO:0006944	systolic blood pressure change measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004574	total cholesterol measurement
EFO:0009932	HMG CoA reductase inhibitor use measurement
EFO:0004530	triglyceride measurement
EFO:0004329	alcohol drinking

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
lead acetate	decreases expression, affects cotreatment	2
sodium arsenite	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
butyraldehyde	decreases expression	1
abrine	decreases expression	1
jinfukang	decreases expression	1
MT19c compound	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Formaldehyde	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Testosterone	decreases expression	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	decreases methylation	1
Vanadates	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.